Commercial Senju launches first-in-class dry eye disease drug in Japan PharmaphorumSenju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.CommercialOphthalmologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaphorum Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market. CommercialOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK again pulls application for leucovorin, touted by FDA as potential autism treatmentNext: With oral obesity race underway, all eyes are on Lilly’s Foundayo launch Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
